ABT-888 (Veliparib): Potent PARP Inhibitor for Chemotherapy Sensitization

Executive Summary: ABT-888 (Veliparib) is a small-molecule inhibitor with high selectivity for PARP1 (Ki = 5.2 nM) and PARP2 (Ki = 2.9 nM) enzymes, critical for DNA repair pathways [APExBIO product page]. It impairs single-strand DNA break repair, effectively sensitizing tumor cells—especially those with microsatellite instability (MSI) or DNA repair gene mutations—to cytotoxic agents and radiation (Pettenger-Willey et al., 2026). ABT-888 demonstrates robust in vivo synergy with chemotherapies such as SN38 and oxaliplatin in colorectal cancer xenografts [internal]. Its high purity (>99.5% by HPLC/NMR), solubility profile, and validated workflows make it a cornerstone for translational oncology research. This review enumerates the precise evidence supporting ABT-888's use and clarifies common pitfalls in its application.

Biological Rationale

Poly (ADP-ribose) polymerase (PARP) enzymes play a crucial role in the cellular DNA damage response by detecting and facilitating repair of single-strand DNA breaks. PARP1 and PARP2 are central to the base excision repair (BER) pathway. Inhibiting PARP activity leads to accumulation of DNA damage, promoting cell death in rapidly dividing tumor cells. This effect is particularly pronounced in cells harboring defects in homologous recombination (HR) repair genes such as BRCA1, MRE11, or RAD50. Tumors with microsatellite instability (MSI) often present such defects, making them more susceptible to PARP inhibition. The rationale for using ABT-888 (Veliparib) is grounded in exploiting these synthetic lethality relationships to enhance the cytotoxicity of DNA-damaging agents while minimizing effects on normal cells (Pettenger-Willey et al., 2026).

Mechanism of Action of ABT-888 (Veliparib)

ABT-888 (Veliparib) is a potent inhibitor of PARP1 and PARP2, with inhibition constants (Ki) of 5.2 nM and 2.9 nM, respectively. Upon binding to the catalytic domain of these enzymes, ABT-888 prevents the formation of poly (ADP-ribose) chains, thereby blocking the recruitment and assembly of DNA repair complexes at sites of single-strand breaks. This inhibition leads to accumulation of unrepaired DNA lesions. During DNA replication, these lesions can convert to double-strand breaks, which are lethal in cells lacking efficient HR repair. In preclinical studies, ABT-888 has been shown to sensitize cancer cells—especially those with HR defects—to a variety of chemotherapeutic agents and ionizing radiation. The compound effectively amplifies DNA damage signaling, engaging caspase pathways and promoting apoptosis in tumor cells [internal].

Evidence & Benchmarks

• ABT-888 inhibits PARP1 and PARP2 with sub-10 nM potency (Ki = 5.2 nM and 2.9 nM, respectively) in cell-free enzymatic assays (APExBIO).
• Microsatellite instability (MSI) tumor models with MRE11 or RAD50 mutations exhibit enhanced sensitivity to ABT-888 in combination with SN38 or oxaliplatin, resulting in significant tumor growth delay in xenografts (internal).
• PARP inhibition by ABT-888 impairs the DNA damage response pathway but does not modulate CLM-induced cytotoxicity in acute leukemia lines, highlighting context-specific efficacy (Pettenger-Willey et al., 2026).
• Solutions of ABT-888 can be prepared at ≥10 mM in DMSO with sonication and warming; solid is stable at -20°C with purity >99.5% confirmed by HPLC and NMR (APExBIO).
• In vivo synergy with DNA-damaging agents is reproducibly demonstrated in colorectal and other tumor xenograft models, as well as in MSI+ cell lines (internal).

This article extends prior analyses by providing a consolidated, citation-rich overview of ABT-888's selectivity and workflow parameters, clarifying distinctions from Maximizing Assay Sensitivity with ABT-888, which focuses on troubleshooting and assay optimization.

Applications, Limits & Misconceptions

ABT-888 is widely used in preclinical research to potentiate the effects of chemotherapeutic agents and radiation in cancer models, particularly those with DNA repair deficiencies. Its application is especially validated in colorectal cancer and other solid tumors with MSI or defective HR. However, studies confirm that PARP inhibition by ABT-888 does not universally sensitize all cancer types or therapeutic contexts. For example, in acute leukemia cell lines exposed to calicheamicin-based ADCs, ABT-888 showed no significant enhancement in cytotoxicity, indicating pathway specificity (Pettenger-Willey et al., 2026). ABT-888 is not approved for diagnostic or therapeutic use in humans and is supplied strictly for research applications. Its stability is optimal at -20°C, and long-term storage of solutions is not recommended due to possible hydrolysis or degradation.

Common Pitfalls or Misconceptions

• ABT-888 does not enhance cytotoxicity of calicheamicin (CLM)-based ADCs in acute leukemia models; its efficacy is context-dependent (Pettenger-Willey et al., 2026).
• PARP inhibition alone is insufficient in tumor models lacking DNA repair pathway deficiencies (e.g., homologous recombination-proficient cells).
• Compound solubility may be suboptimal in aqueous buffers; DMSO or ethanol is required for stock solution preparation (APExBIO).
• Not for diagnostic or therapeutic human use; research-only designation must be strictly observed.
• Long-term storage of ABT-888 solutions at temperatures above -20°C or in non-anhydrous solvents can compromise integrity and experimental outcomes.

Workflow Integration & Parameters

For experimental workflows, stock solutions of ABT-888 should be prepared at ≥10 mM in DMSO, with warming and ultrasonic agitation to maximize solubility. Ethanol can be used as an alternative solvent up to 10.6 mg/mL. Working concentrations should be freshly prepared and stored at -20°C; avoid repeated freeze-thaw cycles. Typical in vitro concentrations range from 0.1 to 10 μM depending on assay design. In vivo studies utilize weight-based dosing adjusted per animal model and route of administration. ABT-888's high purity (>99.5%) is confirmed via HPLC and NMR, and its batch traceability is maintained by APExBIO. For advanced workflow guidance, researchers may consult PARP Inhibitor Workflows for Cancer Research, which offers practical protocols and troubleshooting extensions to the current review.

This article updates and consolidates mechanistic, application, and workflow insights beyond those in Unlocking Cancer Chemosensitization, which emphasizes data interpretation and scenario-driven vendor selection.

Conclusion & Outlook

ABT-888 (Veliparib, SKU A3002) from APExBIO is a validated, high-purity PARP1/2 inhibitor central to modern DNA repair and chemosensitization research. Its robust activity profile, especially in MSI and HR-deficient models, is well documented in both in vitro and in vivo settings. However, its efficacy is context-specific and does not universally potentiate all DNA-damaging agents. Optimal integration into experimental workflows requires strict adherence to solubilization and storage guidelines. As preclinical evidence expands, ABT-888 continues to inform strategies for targeting DNA repair vulnerabilities in cancer biology. For product details and ordering, visit the official ABT-888 (Veliparib) page at APExBIO.